This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hasegawa, K Articles by Hayashi, T Search for Related Content PubMed PubMed Citation Articles by Hasegawa, K Articles by Hayashi, T Social Bookmarking                   What's this?

Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB xNZWF1 mice

Laboratory of Veterinary Pathology, Faculty of Agriculture, Yamaguchi University, Yamaguchi, Japan

T Hayashi

Laboratory of Veterinary Pathology, Faculty of Agriculture, Yamaguchi University, Yamaguchi, Japan, hayasi{at}yamaguchi-u.ac.jp

The effect of synthetic CpG-oligodeoxynucleotides (CpG-ODN) on the development of lupus nephritis during preactive phase (within seven months of age) in autoimmune lupus NZB xNZWF¹(B/WF₁) mice was examined. Treatment of CpG-ODN was started at the age of 2.75 months and continued until 6.25 months. Overt disease began at the age of six months and progressed linearly at the age of 6.75 months in CpG-ODN-treated, but not control ODN-treated (control) groups. Also compared to control group, CpG-ODN-treated mice exhibited a severe glomerulonephritis(GN), with prominent deposits of IgG2a and C3, which paralleled increased titre of IgG2a type anti-nuclear antibody in the blood. Among several cytokines (interleukin, IL-6, IL-4, IL-1a, IL-10, interferon-g and tumor necrosis factor-a) in blood, IL-6 production paralleled the developmentof lupus nephritis. The present study suggests that CpG-ODN may enhance IL-6 production. The role of IL-6 in the development of GN will be discussed.

Key Words: B/WF1 mouse • CpG-ODN • glomerulonephritis • IL-6 • preactive phase

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Bourquin, D. Anz, K. Zwiorek, A.-L. Lanz, S. Fuchs, S. Weigel, C. Wurzenberger, P. von der Borch, M. Golic, S. Moder, et al. Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity J. Immunol., September 1, 2008; 181(5): 2990 - 2998. [Abstract] [Full Text] [PDF]

				S. Hussain and T. L. Delovitch Intravenous Transfusion of BCR-Activated B Cells Protects NOD Mice from Type 1 Diabetes in an IL-10-Dependent Manner J. Immunol., December 1, 2007; 179(11): 7225 - 7232. [Abstract] [Full Text] [PDF]

				A. M. Krieg Antiinfective Applications of Toll-like Receptor 9 Agonists Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294. [Abstract] [Full Text] [PDF]

				R. D. Pawar, P. S. Patole, A. Ellwart, M. Lech, S. Segerer, D. Schlondorff, and H.-J. Anders Ligands to Nucleic Acid-Specific Toll-Like Receptors and the Onset of Lupus Nephritis J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3365 - 3373. [Abstract] [Full Text] [PDF]

				D. Wang, S. A. John, J. L. Clements, D. H. Percy, K. P. Barton, and L. A. Garrett-Sinha Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease Int. Immunol., September 1, 2005; 17(9): 1179 - 1191. [Abstract] [Full Text] [PDF]

				G. Riemekasten and B. H. Hahn Key autoantigens in SLE Rheumatology, August 1, 2005; 44(8): 975 - 982. [Full Text] [PDF]

				R. Brummel and P. Lenert Activation of Marginal Zone B Cells from Lupus Mice with Type A(D) CpG-Oligodeoxynucleotides J. Immunol., February 15, 2005; 174(4): 2429 - 2434. [Abstract] [Full Text] [PDF]